Article

P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway

2022-05-30

Abstract excerpt

<h4>ABSTRACT</h4> Positive transcription elongation factor b (P-TEFb) is the crucial player in RNA polymerase II (Pol II) pause release that has emerged as a promising target in cancer. Because single-agent therapy may fail to deliver durable clinical response, targeting of P-TEFb shall benefit when deployed as a combination therapy. We screened a comprehensive oncology library and identified clinically relevant...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fb037463-d914-53dd-a52d-6e53898b7206
DOI: 10.1101/2022.05.29.493929

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathwayDOI 10.1101/2022.05.29.493929Read

A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant CancersSemantic proximity Read

Pol II degradation activates cell death independently from the loss of transcriptionSemantic proximity Read

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) AntagonistsSemantic proximity Read

A Novel Transcriptional Inhibitor Induces Apoptosis in Tumor Cells and Exhibits Antiangiogenic ActivitySemantic proximity Read

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developmentsSemantic proximity Read

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast CancerSemantic proximity Read

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instabilitySemantic proximity Read

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53Semantic proximity Read

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity Read

Co-inhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer <i>via</i> readthrough transcriptionSemantic proximity Read

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerSemantic proximity Read